BMJ Systematic review of OP trials (69 RCTs, >80k pts) & Fx rates in postmenopausal F shows protective effect of bisphosphonates, PTH receptor agonists, & romosozumab vs PBO. Most effective PTHra > ROMO > Denosumab > bisphosphonates > PBO https://t.co/wKVCUnjmNT MJ